晚期肝细胞癌的新型治疗方法。
Newer treatments for advanced hepatocellular carcinoma.
作者信息
Song Myeong Jun, Bae Si Hyun
机构信息
Division of Hepatology, Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea.
出版信息
Korean J Intern Med. 2014 Mar;29(2):149-55. doi: 10.3904/kjim.2014.29.2.149. Epub 2014 Feb 27.
Abstract
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. The only curative treatment modalities for HCC are surgery, percutaneous ablation, and liver transplantation. Unfortunately, the majority of patients have unresectable disease at diagnosis. Therefore, effective treatment options are needed for patients with advanced HCC. The current standard treatment for patients with advanced HCC, according to the Barcelona Clinic Liver Cancer staging system, is the multikinase inhibitor sorafenib. Other alternative therapies are required, due to the limited treatment response to, and tolerance of, this molecular target agent. Clinical trials of hepatic artery infusion chemotherapy, radioembolization, and multimodal treatments have shown favorable results in advanced HCC patients. This article introduces new treatment modalities for advanced HCC and discusses future therapeutic possibilities.
摘要
肝细胞癌（HCC）是全球最常见的癌症之一。HCC唯一的根治性治疗方式是手术、经皮消融和肝移植。不幸的是，大多数患者在诊断时已处于不可切除阶段。因此，晚期HCC患者需要有效的治疗选择。根据巴塞罗那临床肝癌分期系统，晚期HCC患者目前的标准治疗是多激酶抑制剂索拉非尼。由于这种分子靶向药物的治疗反应和耐受性有限，还需要其他替代疗法。肝动脉灌注化疗、放射性栓塞和多模式治疗的临床试验在晚期HCC患者中已显示出良好效果。本文介绍了晚期HCC的新治疗方式，并探讨了未来的治疗可能性。
相似文献
1
Newer treatments for advanced hepatocellular carcinoma.晚期肝细胞癌的新型治疗方法。
Korean J Intern Med. 2014 Mar;29(2):149-55. doi: 10.3904/kjim.2014.29.2.149. Epub 2014 Feb 27.
2
Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial.选择性内照射治疗单次给药与索拉非尼持续治疗用于局部晚期肝细胞癌的对比研究（SIRveNIB）：一项III期随机对照试验的研究方案
BMC Cancer. 2016 Nov 7;16(1):856. doi: 10.1186/s12885-016-2868-y.
3
Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.钇-90微球放射性栓塞术与索拉非尼治疗晚期肝细胞癌的比较（SARAH）：一项随机对照试验的研究方案
Trials. 2014 Dec 3;15:474. doi: 10.1186/1745-6215-15-474.
4
Complete remission of advanced hepatocellular carcinoma by radiofrequency ablation after sorafenib therapy.索拉非尼治疗后经射频消融实现晚期肝细胞癌完全缓解
World J Gastroenterol. 2015 Feb 28;21(8):2568-72. doi: 10.3748/wjg.v21.i8.2568.
5
Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.钇-90微球放射性栓塞治疗不可切除的肝细胞癌
Cochrane Database Syst Rev. 2016 Feb 16;2:CD011313. doi: 10.1002/14651858.CD011313.pub2.
6
Intermediate hepatocellular carcinoma: current treatments and future perspectives.中晚期肝细胞癌：当前的治疗方法和未来展望。
Ann Oncol. 2013 Apr;24 Suppl 2:ii24-9. doi: 10.1093/annonc/mdt054.
7
Complete Remission of Unresectable Hepatocellular Carcinoma After Combined Sorafenib and Adjuvant Yttrium-90 Radioembolization.索拉非尼联合辅助性钇-90放射性栓塞后不可切除肝细胞癌的完全缓解
Cancer Biother Radiopharm. 2016 Mar;31(2):65-9. doi: 10.1089/cbr.2015.1905.
8
Interventional treatment for unresectable hepatocellular carcinoma.不可切除肝细胞癌的介入治疗
World J Gastroenterol. 2014 Oct 7;20(37):13453-65. doi: 10.3748/wjg.v20.i37.13453.
9
Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status.比较有大血管侵犯和经导管动脉化疗栓塞耐药状态的晚期肝细胞癌患者行肝动脉灌注化疗和索拉非尼治疗的临床结局。
J Gastroenterol Hepatol. 2018 Oct;33(10):1780-1786. doi: 10.1111/jgh.14152. Epub 2018 May 10.
引用本文的文献
1
Hesperetin and Capecitabine Abate 1,2 Dimethylhydrazine-Induced Colon Carcinogenesis in Wistar Rats via Suppressing Oxidative Stress and Enhancing Antioxidant, Anti-Inflammatory and Apoptotic Actions.橙皮素和卡培他滨通过抑制氧化应激并增强抗氧化、抗炎和凋亡作用，减轻1,2-二甲基肼诱导的Wistar大鼠结肠癌发生。
Life (Basel). 2023 Apr 11;13(4):984. doi: 10.3390/life13040984.
2
Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma - The Changing Tides.门静脉肿瘤血栓形成与肝细胞癌——变化的趋势
J Hepatocell Carcinoma. 2021 Sep 7;8:1089-1115. doi: 10.2147/JHC.S318070. eCollection 2021.
3
Determinants of pain in advanced HCC patients recieving hepatic artery infusion chemotherapy.晚期 HCC 患者接受肝动脉灌注化疗后疼痛的决定因素。
Invest New Drugs. 2021 Apr;39(2):394-399. doi: 10.1007/s10637-020-01009-x. Epub 2020 Oct 1.
4
Value of surgical resection compared to transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein tumor thrombus: A meta-analysis of hazard ratios from five observational studies.与经动脉化疗栓塞术相比，手术切除在治疗伴有门静脉癌栓的肝细胞癌中的价值：来自五项观察性研究的风险比的荟萃分析。
Ann Hepatobiliary Pancreat Surg. 2020 Aug 31;24(3):243-251. doi: 10.14701/ahbps.2020.24.3.243.
5
Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome Analysis.经动脉化疗栓塞术治疗初治和复发性肝细胞癌：倾向评分匹配结局分析。
Dig Dis Sci. 2019 Dec;64(12):3660-3668. doi: 10.1007/s10620-019-05701-8. Epub 2019 Jun 11.
6
Comparison of clinical outcomes between sorafenib and hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma: A STROBE-compliant article.索拉非尼与肝动脉灌注化疗治疗晚期肝细胞癌的临床疗效比较：一篇符合STROBE标准的文章。
Medicine (Baltimore). 2018 Apr;97(17):e0611. doi: 10.1097/MD.0000000000010611.
7
Endocan silencing induces programmed cell death in hepatocarcinoma.内源性血管生成素沉默诱导肝癌细胞程序性死亡。
Oncol Lett. 2017 Nov;14(5):5333-5339. doi: 10.3892/ol.2017.6857. Epub 2017 Aug 31.
8
Hepatocellular Carcinoma: Implications for Asia-Pacific Oncology Nurses.肝细胞癌：对亚太地区肿瘤护理人员的启示
Asia Pac J Oncol Nurs. 2017 Apr-Jun;4(2):98-103. doi: 10.4103/2347-5625.204497.
9
Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.去γ-羧基凝血酶原通过激活Raf/MEK/ERK和PI3K/Akt/mTOR信号通路拮抗索拉非尼对人肝细胞癌的作用。
Oncotarget. 2016 Jun 14;7(24):36767-36782. doi: 10.18632/oncotarget.9168.
10
Subtractive Cell-SELEX Selection of DNA Aptamers Binding Specifically and Selectively to Hepatocellular Carcinoma Cells with High Metastatic Potential.用于筛选与具有高转移潜能的肝癌细胞特异性且选择性结合的DNA适配体的消减细胞SELEX筛选法
Biomed Res Int. 2016;2016:5735869. doi: 10.1155/2016/5735869. Epub 2016 Mar 28.
本文引用的文献
1
Radioembolization With Yttrium-90 Resin Microspheres in Hepatocellular Carcinoma: A Multicenter Prospective Study.钇-90树脂微球放射性栓塞治疗肝细胞癌：一项多中心前瞻性研究
Am J Clin Oncol. 2015 Oct;38(5):495-501. doi: 10.1097/COC.0b013e3182a78dba.
2
Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses.索拉非尼单药治疗与索拉非尼联合经动脉化疗栓塞治疗晚期肝细胞癌的疗效比较：倾向评分分析结果。
Radiology. 2013 Nov;269(2):603-11. doi: 10.1148/radiol.13130150. Epub 2013 Jul 17.
3
Combination treatment of localized concurrent chemoradiation therapy and transarterial chemoembolization in locally advanced hepatocellular carcinoma with intrahepatic metastasis.局部晚期合并肝内转移肝细胞癌同步放化疗联合经肝动脉化疗栓塞治疗。
Cancer Chemother Pharmacol. 2013 Jan;71(1):165-73. doi: 10.1007/s00280-012-1993-9. Epub 2012 Oct 19.
4
Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study.钇 90 放射性栓塞治疗中晚期肝细胞癌：一项 2 期研究。
Hepatology. 2013 May;57(5):1826-37. doi: 10.1002/hep.26014. Epub 2013 Mar 22.
5
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial.索拉非尼治疗晚期肝细胞癌患者的疗效和安全性：III 期索拉非尼亚太临床试验的亚组分析。
Eur J Cancer. 2012 Jul;48(10):1452-65. doi: 10.1016/j.ejca.2011.12.006. Epub 2012 Jan 10.
6
Radiotherapeutic strategies in the management of hepatocellular carcinoma.肝癌的放射治疗策略。
Oncology. 2011;81 Suppl 1:123-33. doi: 10.1159/000333275. Epub 2011 Dec 22.
7
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma and future treatments for the poor responders.经肝动脉灌注化疗治疗晚期肝细胞癌及对无应答者的未来治疗方法。
Hepatol Res. 2012 Apr;42(4):340-8. doi: 10.1111/j.1872-034X.2011.00938.x. Epub 2011 Dec 13.
8
Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma.肝细胞癌的信号通路和分子靶向治疗。
Dig Dis. 2011;29(3):289-302. doi: 10.1159/000327562. Epub 2011 Aug 9.
9
Radioembolization for hepatocellular carcinoma.肝癌的放射性栓塞治疗。
J Hepatol. 2012 Feb;56(2):464-73. doi: 10.1016/j.jhep.2011.07.012. Epub 2011 Aug 2.
10
Clinical implications of the body surface area method versus partition model dosimetry for yttrium-90 radioembolization using resin microspheres: a technical review.体表面积法与分区模型剂量学在钇-90 树脂微球放射性栓塞中的临床意义：技术综述。
Ann Nucl Med. 2011 Aug;25(7):455-61. doi: 10.1007/s12149-011-0499-6. Epub 2011 Jun 4.
Zotero 插件